Learn about Psychedelic Psychopharmacology in our 12-week reading and study group or on-demand webinar. See the individual courses for an in-depth description of each offering.
Learning Objectives
Describe pharmacokinetic properties of psilocybin to predict potential drug interactions and adverse effects.
Describe pharmacokinetic properties of ayahuasca to predict potential drug interactions and adverse effects.
Describe pharmacokinetic properties of MDMA to predict potential drug interactions and adverse effects.
Describe pharmacokinetic properties of ketamine to predict potential drug interactions and adverse effects.
Explain how the pharmacodynamics of psilocybin affects clinical and serological biomarkers.
Explain how the pharmacodynamics of ayahuasca affects clinical and serological biomarkers.
Explain how the pharmacodynamics of MDMA affects clinical and serological biomarkers.
Explain how the pharmacodynamics of ketamine affects clinical and serological biomarkers.
Discuss the effects of psilocybin on neural network function.
Discuss the effects of ayahuasca on neural network function.
Discuss the effects of MDMA on neural network function.
Discuss the effects of ketamine on neural network function.
Psychedelic Psychopharmacology with Dr. Kelan Thomas has been my favorite class offered in the entire program. Dr. Thomas is highly experienced in his field and brings this expertise to the classroom. I appreciated his availability during class and outside of class to answer questions related to content discussions each week. The research presented is well organized and he covers the areas that are pertinent to students continued knowledge in the field of psychedelics and psychopharmacology.
